AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Oral Science and Homeostatic Medicine Article
PDF (713.7 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review Article | Open Access

Targeted therapy, immunotherapy, and chemotherapy for chordoma

Xue Yang1 , Parker Li2, Zhuang Kang3, Wenbin Li3 ( )
Capital Medical University, Beijing 10000, China
Shanghai Jiao Tong University School of Medicine, Beijing 10000, China
Beijing Tiantan Hospital, Beijing 10000, China

Xue Yang and Parker Li collect data and write articles, while Zhuang Kang and Wenbin Li are responsible for correcting and revising articles.

Show Author Information

Abstract

Chordoma is a rare bone tumor often present in the skull base and spine. In addition, it is not sensitive to radiotherapy that surgical resection is of great significance for the treatment of chordoma. Residual tumors that cannot be surgically removed usually lead to tumor recurrence. Studies have shown that chordoma will be accompanied by multiple gene mutations, such as PDGFR, EGFR, HER2, VEGFR, and mTOR, and interact with the host immune system to promote tumor progression. Targeted therapy and immunotherapy can improve the prognosis of chordoma patients to some extent. This review focuses on the clinical trials related to targeted therapy, immunotherapy, and chemotherapy of chordoma.

Keywords

ChordomaTargeted therapyImmunotherapyChemotherapy

References

【1】
【1】
 
 
Crossref Google Scholar
Oral Science and Homeostatic Medicine
Volume 2,
October 2023
DOI: 10.1007/s44194-022-00017-8

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Cite this Report
Close
Close
Cite this article:
Yang X, Li P, Kang Z, et al. Targeted therapy, immunotherapy, and chemotherapy for chordoma. Oral Science and Homeostatic Medicine, 2023, 2. https://doi.org/10.1007/s44194-022-00017-8

629

Views

39

Downloads

10

Crossref
Received: 20 September 2022
Accepted: 22 November 2022
Published: 06 February 2023
© The Author(s) 2023.

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.